



The Outlook for RNAi

Accelerating drug discovery and the development of RNAi therapeutics



The Outlook for RNAi

Accelerating drug discovery and the development of RNAi therapeutics

Report overview


The RNAi market achieved global sales of just over \$1bn in 2004 and is projected to reach \$2.5bn by 2010, a compound annual growth rate (CAGR) 2004-2010 of 14%. 'The Outlook for RNAi: Accelerating drug discovery and the development of RNAi therapeutics' analyzes the latest trends in the RNAi market, allowing pharmaceutical companies to decide which areas of RNAi technologies to invest in, to improve drug attrition rates and develop new therapeutic agents. **RNAi therapeutics are forecast to generate sales of around \$1bn by 2015 and this market has significant potential, should companies be able to overcome delivery constraints.**

This report analyzes future trends of RNAi and provides detailed insight into the most effective use of this novel technology in the drug discovery process. This report details recent alliances and acquisitions being made by big pharmaceutical companies, allowing you to assess their investment in this new and rapidly advancing field.

Key features

- Value and breakdown of sub-sector performances of the RNAi market 2004-2015
- In-depth examination of key companies involved in the development of RNAi therapeutics, key therapy areas, the phase of clinical development, potential drug sales and patent position
- Analysis of the strengths and weaknesses of different approaches to RNAi delivery and selectivity
- Future direction of RNAi research and the development of second generation siRNAs, miRNAs and multifunctional siRNAs.

Figure 7.47: Growth in the RNAi market 2004-2010



Source: The Outlook for RNAi

Key findings

- The two key challenges to RNAi-based therapies are ensuring efficient drug delivery and avoiding 'off-target' gene suppression.
- RNAi-based screens have provided new opportunities for the discovery and validation of novel therapeutic targets and offer new hope for "smarter targets", ultimately having a significant effect on the drug development process and drug attrition rates.
- Companies are already developing "second generation" gene silencing agents including: multifunctional siRNAs, hyperfunctional or superactive siRNAs, no-ribose siRNAs and siRNAs conjugated with small molecule drugs, which may have critical advantages over their predecessors.



The Outlook for RNAi

Accelerating drug discovery and the development of RNAi therapeutics

TABLE OF CONTENTS

CHAPTER 1: CURRENT RNA TECHNOLOGIES

- Introduction
- History of RNAi
 - From DNA to RNA to proteins
 - mRNA regulation
 - Gene expression
- Antisense technology
- History of RNAi
 - Oligonucleotides (OGNs)
 - Peptide nucleic acids (PNAs)
 - Locked nucleic acids (LNA)
 - Triple helix DNA or triple helix-forming oligonucleotides (TFOs)
 - Ribozymes
 - DNAzymes
 - Aptamers
 - RNA interference
 - siRNAs versus dsRNA
 - siRNAs versus shRNA
- Conclusions

CHAPTER 2: DESIGN, PRODUCTION AND DELIVERY OF RNAI

- Introduction
- Cost-effective RNA design
- Cost-effective synthesis of siRNA
 - Chemical synthesis
 - In vitro transcription
 - DICER reaction
 - Expression vectors
 - DNA-directed RNAi (ddRNAi)
 - Expressed interfering RNA (eiRNA)
 - Conclusions
- Improvements in siRNA stability
 - Chemical modifications
 - Formulation modifications
 - Small molecule conjugation
 - Synthetic vector systems
 - Conclusion
- RNAi delivery options
 - Viral vectors
 - Conclusion

CHAPTER 3: THE FUTURE OF RNAI IN RESEARCH AND DRUG DISCOVERY

- Applications of RNAi in research
 - Functional genomics
 - Signaling pathways
- Applications of RNAi in drug discovery
 - Gene expressions studies
 - Target validation
 - Toxicogenomics
- Applications of RNAi in drug development
 - Transgenics
- The impact of RNAi in R&D

CHAPTER 4: EMERGING RNA TECHNOLOGIES AND FUTURE TRENDS

- Introduction
 - Shift from antisense to RNAi
- Ocular diseases
 - Age-related Macular Degeneration (AMD)
 - Key RNAi players
 - Diabetic Retinopathy (DR)
 - Key RNAi players
- Infectious diseases
 - Hepatitis C virus (HCV)
 - Key RNAi players
 - HIV
 - CMV (cytomegalovirus)
 - Key RNAi players
- Respiratory
 - Respiratory Syncytial Virus (RSV)
 - Key RNAi players
 - Asthma
 - Key RNAi players
 - Cystic fibrosis
 - Key RNAi players
- Neurological diseases
 - Huntingdon's disease (HD)
 - Key RNAi players
 - Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease)
 - Key RNAi players
 - Spinal Cord Injury (SCI)
 - Key RNAi players
 - Parkinson's disease (PD)
 - Alzheimer's disease (AD)
 - Pain



The Outlook for RNAi

Accelerating drug discovery and the development of RNAi therapeutics

CHAPTER 4: EMERGING RNA TECHNOLOGIES AND FUTURE TRENDS (CONTINUED)

- Oncology
 - Angiogenesis
 - Key RNAi players
 - Oncogenes
 - Key RNAi players
 - Drug resistance and enhancement
 - Key RNAi players
 - Conclusions on RNAi in oncology
- Cardiovascular diseases
 - Key RNAi players
- Metabolic disorders
 - Diabetes
 - Key RNAi players
- The future role of RNAi-based therapeutics

CHAPTER 5: EMERGING RNA TECHNOLOGIES AND FUTURE TRENDS

- Second generation siRNAs
 - Multifunctional siRNAs
 - Hyperfunctional or superactive siRNAs
 - No-ribose small inhibitory nucleic acids (siNAs)
 - siRNAs conjugated with small molecule drugs
- Alternative RNA based therapies:
 - Micro RNAs (miRNAs)
 - miRNA processing
 - miRNA in embryonic development
 - miRNA in neurological disorders
 - miRNA in cancer
 - Future direction of miRNA research
 - Small nucleolar RNAs (snoRNAs)
 - Aptamers

CHAPTER 6: PATENTS AND STRATEGIC ALLIANCES IN RNAi TECHNOLOGY

- Patents for siRNA reagents
- Patents for siRNA therapeutics
 - Alnylam Pharmaceuticals (Cambridge, MA, US)
 - Patent position
 - Strategic alliances, 2003-2005
 - Benitec Ltd (Queensland, Australia)
 - Patent position
 - Strategic alliances, 2003-2005
 - Sirna Therapeutics (formerly Ribozyme Pharmaceuticals)
 - Patent position
 - Strategic alliances, 2003-2005

- Acuity Pharmaceuticals (Philadelphia, PA, US)
 - Patent position
 - Strategic alliances, 2003-2005
- Atugen AG (Dresden, Germany)
 - Patent position
 - Strategic alliances, 2003-2005
- CytRx Labs (Los Angeles, MA, USA)
 - Patent position
 - Strategic alliances, 2003-2005
- Intradigm (Rockville, MD, USA)
- Nucleonics Inc. (Horsham, PA, USA)
- Future impact of IP on RNAi research

CHAPTER 7: RNAi MARKETS AND TRENDS

- Introduction
- The RNAi market
- Market size and future trends
 - siRNA synthesis and delivery
 - RNAi reagents
 - RNAi in drug discovery and target validation
 - RNAi therapeutics

LIST OF FIGURES (ABRIDGED)

- Figure 1.1: History of RNAi
- Figure 1.2: Schematic of DNA, genes and proteins
- Figure 1.3: Schematic of gene splicing
- Figure 1.4: Major mechanisms for antisense OGN action
- Figure 1.5: Mechanism of preventing translation using OGN technology
- Figure 1.6: Chemical structure of PNA versus DNA
- Figure 1.7: Chemical structure of LNA versus RNA
- Figure 1.8: Mechanism of preventing translation using triple helix DNA technology
- Figure 1.9: Mechanism of preventing translation using ribozymes
- Figure 1.10: Schematic of the mechanism of gene silencing by RNAi
- Figure 1.11: Schematic of the mechanism of shRNAs
- Figure 2.12: Advantages and disadvantages of siRNA synthesis methods

FAX BACK TO: **+44 (0) 207 900 6688**

or scan and e-mail to
marketing@globalbusinessinsights.com

I would like to order the following report...

1

(Please use **BLOCK CAPITALS**)

Hard Copy (extra £50/€75/\$95)
Please allow 28 days for delivery

Interactivity (extra £50/€75/\$95)
Search, customize & translate content

Please select a license type:

2

	GB£	EUR€	US\$
<input type="checkbox"/> Single User (eCopy) <small>Access permitted for one individual only</small>	1995	2880	3835
<input type="checkbox"/> Site License <small>Access permitted for every individual based at one location</small>	3790	5470	7285
<input type="checkbox"/> Company License <small>Global access for every individual member of staff at the company</small>	7475	9180	12180

To ask a question about license types, email: marketing@globalbusinessinsights.com

Communications Feedback

Please let us know if any of the following factors influenced your purchase...

- Email/Fax/Postal promotion
- Trade Press
- Brochure
- My Account Manager
- Table of Contents
- Conference materials
- Colleague Recommendation
- Website/web search

Recipient details (if different from Payor)

Title: Mr/Mrs/Ms **(Please use BLOCK CAPITALS)**

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____ Fax: _____

Company details

3

Company name: _____

EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:

Purchase Order Number (if required): _____

Payment method

4

Please indicate your preferred currency: GB£ EUR€ US\$

Total order value is _____

I will forward a check payable to Business Insights Limited.

Please invoice my company (please complete invoice address below)

I would like to pay by bank transfer (email address required)

Debit my credit/charge card: Amex Visa Mastercard

Card No _____

Expiry Date ____ / ____ Signature _____

Payor details

5

Title: Mr/Mrs/Ms **(Please use BLOCK CAPITALS)**

First Name: _____ Last Name: _____

Email: _____

Job Title: _____

Department: _____

Address: _____

City: _____ State/Province: _____

Country: _____ Post Code/ZIP: _____

Tel: _____

Fax: _____

Sign here to confirm your order:

ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

By completing this form you agree that the data in the form will be used for the purpose of processing your order. We may also use your data to keep you informed of our products and services. As an international organization, Business Insights may need to process your data in countries which do not have data protection laws, or which have standards lower than the EU. Business Insights seeks to protect your personal data. You have a right to see and correct your data by writing to us. In case of queries, contact info@globalbusinessinsights.com. Please tick the relevant box(es) if you would not like Business Insights to contact you by:

Email Post Fax Phone

Occasionally, our client list is made available to other companies for carefully selected correspondence. Please check here if you do not wish to receive such correspondence by:

Email Post

This order is subject to our standard terms and conditions, a copy of which is available on request.

Marketing Department
marketing@globalbusinessinsights.com

Code Ref: Website

www.globalbusinessinsights.com

+44 (0) 20 7551 9700

Registered Office: Business Insights Ltd, Mortimer House,
37-41 Mortimer Street, London W1T 3JH.
UK Registered Number: 05006037